$1.02
(Market cap
$16,651 Mln
Revenue (TTM)
$868 Mln
P/E Ratio
29.4
P/B Ratio
29.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-20.7
-
Debt to Equity
0.8
-
Book Value
$--
-
EPS
$7.7
-
Face value
--
-
Shares outstanding
65,592,830
10 Years Aggregate
CFO
€-2,184.14 Mln
EBITDA
€-2,320.00 Mln
Net Profit
€-2,450.27 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
| 19.3 | -2.4 | 12.3 | 51.9 | 42.7 | 17.6 | 34.6 |
|
BSE Sensex
| -9.3 | -0.4 | -0.7 | -5.8 | 5.0 | 7.9 | 10.6 |
|
S&P Midcap 400
| 13.5 | -0.5 | 4.3 | 18.0 | 12.1 | 7.4 | 9.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
| 54.9 | 9.2 | 3.1 | -9.2 | -19.3 | 19.9 | 122.1 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Ascendis Pharma A/S - ADR
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients... with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Read more
-
President, CEO, Member of Executive Board & Executive Director
Mr. Jan Moller Mikkelsen
-
President, CEO, Member of Executive Board & Executive Director
Mr. Jan Moller Mikkelsen
-
Headquarters
Hellerup
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ascendis Pharma A/S - ADR
What is the current share price of Ascendis Pharma A/S - ADR Today?
The share price of Ascendis Pharma A/S - ADR is $254.44 (NASDAQ) as of 28-Jul-2026 16:00 EDT. Ascendis Pharma A/S - ADR has given a return of 42.71% in the last 3 years.
What is the current PB & PE ratio of Ascendis Pharma A/S - ADR?
The P/E ratio of Ascendis Pharma A/S - ADR is 29.42 times as on 24-Jul-2026.
The P/B ratio of Ascendis Pharma A/S - ADR is 29.75 times as on 24-Jul-2026, a 484 premium to its peers’ median range of 5.09 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-59.39
|
-79.92
|
|
2024
|
-21.12
|
-75.54
|
|
2023
|
-14.65
|
-48.41
|
|
2022
|
-11.73
|
25.97
|
|
2021
|
-19.29
|
8.37
|
What is the 52 Week High and Low of Ascendis Pharma A/S - ADR?
The 52-week high and low of Ascendis Pharma A/S - ADR are Rs 282.15 and Rs 160.86 as of 29-Jul-2026.
What is the market cap of Ascendis Pharma A/S - ADR?
Ascendis Pharma A/S - ADR has a market capitalisation of $ 16,651 Mln as on 24-Jul-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Ascendis Pharma A/S - ADR?
Before investing in Ascendis Pharma A/S - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.